66 Recruiting Studies Using Pomalidomide
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Pomalidomide
Ixazomib + Pomalidomide + Dexamethasone In MM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Recurrent Multiple Myeloma
View Study & Checklist ➔Pomalidomide Treatment in Patients With Kaposi Sarcoma
📍 UC San Diego Moores Cancer Center — La Jolla, California
Skin Kaposi Sarcoma
View Study & Checklist ➔A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Kaposi Sarcoma
View Study & Checklist ➔Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Acute Myeloid Leukemia
View Study & Checklist ➔Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Tucson, Arizona
Multiple Myeloma
View Study & Checklist ➔A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
📍 Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407 — Tucson, Arizona
Multiple Myeloma
View Study & Checklist ➔Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
📍 Colorado Blood Cancer Institute (Sarah Cannon) — Denver, Colorado
Multiple Myeloma in Relapse
View Study & Checklist ➔Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
📍 University of California San Diego — La Jolla, California
Myeloma
View Study & Checklist ➔A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
📍 Weill Cornell Medicine - Multiple Myeloma Center — New York, New York
Multiple Myeloma
View Study & Checklist ➔Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
📍 Boston Medical Center — Boston, Massachusetts
AL Amyloidosis
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
📍 University of Arkansas for Medical Sciences /ID# 243096 — Little Rock, Arkansas
Relapsed/Refractory Multiple Myeloma
View Study & Checklist ➔Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
📍 Emory University — Atlanta, Georgia
Multiple Myeloma
View Study & Checklist ➔Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
📍 Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Multiple Myeloma
View Study & Checklist ➔SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
📍 Mohtaseb Cancer Center and Blood Disorders Site Number : 8400028 — Bullhead City, Arizona
Plasma Cell Myeloma Recurrent
View Study & Checklist ➔Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
📍 OHSU Knight Cancer Institute — Portland, Oregon
Recurrent Plasma Cell Myeloma
View Study & Checklist ➔A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 Alaska Oncology and Hematology LLC — Anchorage, Alaska
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
📍 UCSF Fresno — Clovis, California
Multiple Myeloma
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
📍 GSK Investigational Site — Salvador, Estado de Bahia
Multiple Myeloma
View Study & Checklist ➔Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 The University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study of Daratumumab
📍 University of Miami Sylvester Cancer Center — Miami, Florida
Multiple Myeloma
View Study & Checklist ➔Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Recurrent Multiple Myeloma
View Study & Checklist ➔A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
📍 The University of Arizona Cancer Center — Tucson, Arizona
Multiple Myeloma
View Study & Checklist ➔Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Atlanta, Georgia
Multiple Myeloma
View Study & Checklist ➔A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Plasma Cell Myeloma
View Study & Checklist ➔Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
📍 Stanford University — Palo Alto, California
Amyloid
View Study & Checklist ➔Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
📍 University of Colorado Hospital — Aurora, Colorado
Multiple Myeloma in Relapse
View Study & Checklist ➔A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
Multiple Myeloma
View Study & Checklist ➔A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Multiple Myeloma
View Study & Checklist ➔A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham - Main /ID# 261434 — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
📍 University of Arizona Cancer Center /ID# 285339 — Tucson, Arizona
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
📍 City of Hope Medical Center — Duarte, California
Recurrent Plasma Cell Myeloma
View Study & Checklist ➔A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Relapsed and/or Refractory Multiple Myeloma (RRMM)
View Study & Checklist ➔A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
📍 University of Alabama At Birmingham Hospital — Birmingham, Alabama
Relapsed/Refractory Multiple Myeloma
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
📍 University of Alabama at Birmingham — Birmingham, Alabama
Relapsed or Refractory Multiple Myeloma (RRMM)
View Study & Checklist ➔Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Relapsed Cancer
View Study & Checklist ➔Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Recurrent B Acute Lymphoblastic Leukemia
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
📍 University of Southern California /ID# 272414 — Los Angeles, California
Multiple Myeloma
View Study & Checklist ➔Selinexor and Backbone Treatments of Multiple Myeloma Patients
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Diffuse Large Cell Lymphoma
View Study & Checklist ➔Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Multiple Myeloma
View Study & Checklist ➔Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
📍 Emory University/Winship Cancer Institute — Atlanta, Georgia
Plasma Cell Myeloma
View Study & Checklist ➔AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
📍 Research Site — Duarte, California
Multiple Myeloma
View Study & Checklist ➔Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Arizona — Phoenix, Arizona
Multiple Myeloma Refractory
View Study & Checklist ➔Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Haematological Malignancy
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 City of Hope — Duarte, California
Multiple Myeloma
View Study & Checklist ➔A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
📍 Colorado Blood Cancer Institute — Denver, Colorado
Multiple Myeloma
View Study & Checklist ➔Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
📍 Winship Cancer Institute of Emory University- Site Number : 8400010 — Atlanta, Georgia
Plasma Cell Myeloma Refractory
View Study & Checklist ➔Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
Multiple Myeloma
View Study & Checklist ➔A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
📍 GSK Investigational Site — Bullhead City, Arizona
Multiple Myeloma
View Study & Checklist ➔A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
📍 Research Site — Gilbert, Arizona
Relapsed Refractory Multiple Myeloma
View Study & Checklist ➔Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Viral Associated Malignancies
View Study & Checklist ➔A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
📍 Clovis Community Medical Center — Clovis, California
Multiple Myeloma
View Study & Checklist ➔Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Recurrent Multiple Myeloma
View Study & Checklist ➔A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
📍 Scripps Clinic Torrey Pines — La Jolla, California
Multiple Myeloma
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Los Alamitos, California
Multiple Myeloma
View Study & Checklist ➔A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
📍 University of California Los Angeles (UCLA) — Los Angeles, California
Relapsed Refractory Multiple Myeloma (RRMM)
View Study & Checklist ➔A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
📍 Local Institution - 0366 — Los Alamitos, California
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
📍 Infirmary Cancer Care — Mobile, Alabama
Multiple Myeloma
View Study & Checklist ➔